Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Possibly Marketed Outside US

2

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

prostanoid metabolic process

2

DNA polymerase beta

1

Human immunodeficiency virus type 1 reverse transcriptase

1

polymerase (DNA directed), alpha 1, catalytic subunit

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

Phase I

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2017

2

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Atopic dermatitis

2

Mastalgia

2

Multiple sclerosis

1

Obesity-related metabolic disorders

1

Psychosis

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

Palliative

1

Preventing

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Osbond, J.M. et al.

2

Tsujimoto, M.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

FDA UNII

3

PUBCHEM

3

CHEBI

2

DSLD

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

DERMATOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

OTHER DERMATOLOGICAL PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER DERMATOLOGICAL PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other dermatologicals

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

NERVONIC ACID

91OQS788BE

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

DNA polymerase beta

polymerase (DNA directed), alpha 1, catalytic subunit

Human immunodeficiency virus type 1 reverse transcriptase

Conditions:

Multiple sclerosis

Obesity-related metabolic disorders

Nervonic acid is a long chain unsaturated fatty acid that is enriched in sphingomyelin. It consists of choline, sphingosine, phosphoric acid, and fatty acid. Nervonic acid may enhance the brain functions and prevent demyelination (Chemical Land21). R...

esearch shows that there is negative relationship between nervonic acid and obesity-related risk factors. Demyelination in adrenoleukodystrophy (ALD) is associated with an accumulation of very long chain saturated fatty acids stemming from a genetic defect in the peroxisomal beta oxidation system responsible for the chain shortening of these fatty acids. Sphingolipids from post mortem ALD brain have decreased levels of nervonic acid, 24:1(n-9), and increased levels of stearic acid, 18:0. Nervonic acid (C24:1), a component of membrane sphingolipids and phosphatidylethanolamines, may be a useful predictor of chronic kidney disease mortality and diabetes. Nervonic acid oils are being studied for pharmaceutical, nutraceutical and industrial applications. Nervonic acid is a major component of Lunaria oil. There is increasing evidence that dietary supplementation with nervonic acid is healthy for babies and infants during the early stage of brain development. Nervonic acid has been reported to reduce the shaking associated with Parkinson’s disease and the numbness caused by multiple sclerosis. It also has potential for treating schizophrenia and reducing early Alzheimer’s symptoms.

GAMOLENIC ACID

78YC2MAX4O

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2017

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

prostanoid metabolic process

Conditions:

Atopic dermatitis

Gamolenic acid also known as gamma-lonolenic acid is a natural component of Oenothera biennis L. (Evening Primrose). Gamolenic acid was used for the treatment of breast painand atopic dermatitis in Europe, although now the drug is withdrawn from the ...

market (there is no safety issue associated with the withdrawal of the licences). The mechanism of action of gamolenic acid is connected with its interaction with prostanoid pathway.

SODIUM .GAMMA.-LINOLENATE

L4WFA9KRB5

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2017

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

prostanoid metabolic process

Conditions:

Atopic dermatitis

Gamolenic acid also known as gamma-lonolenic acid is a natural component of Oenothera biennis L. (Evening Primrose). Gamolenic acid was used for the treatment of breast painand atopic dermatitis in Europe, although now the drug is withdrawn from the ...

market (there is no safety issue associated with the withdrawal of the licences). The mechanism of action of gamolenic acid is connected with its interaction with prostanoid pathway.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1